Platelet-derived growth factor receptor beta (PDGFRβ) affects in numerous human cancers and has been recognized as a promising molecular target for cancer therapies. The overexpression of PDGFRβ could be a biomarker for cancer diagnosis. 
of an element or a functional group in the bioactive molecule with another type of a radioactive element, such as a radiohalogen, or another functional group with chemical similarity containing a radionuclide 12 ; and (iii) addition of a radioactive metal with a chelator 13, 14 . Because most organic molecules contain C, N, and O elements, replacing one of these elements with 11 C, 13 N, or 15 O can lead to the development of a radiotracer. This replacement normally does not change the biological activity of the original molecule, and allows for the study of the metabolism or pharmacokinetics of such molecules 12 . However, this type of tracer has limited use because of the short half-lives of 11 C (t 1/2 = 20 min), 13 N (t 1/2 = 10 min), and 15 O (t 1/2 = 2 min). Although the influence is generally smaller than radiometal incorporation, substitution with a radiohalogen could influence affinity for the molecular target, biodistribution, and metabolism of bioactive compounds 13 . Therefore, the choice of radionuclides and the introduced position should be optimized to develop radiotracers with a radiohalogen.
18 F (t 1/2 = 110 min) is frequently used as positron emission tomography (PET) imaging radionuclide. Labeling with fluorine normally requires a different method than labeling with other halogens, such as bromine and iodine because of the short half-life and distinct physical property of fluorine 12 .
124
I has been an interesting radionuclide for clinical and experimental PET because of its relatively longer half-life (t 1/2 = 4.2 day) and chemical properties, namely the same labeling methods for 123 I and 131 I, which have been frequently used in clinical nuclear medicine, can be available 12 . However, the decay properties of 124 I are not ideal for PET because the positron abundance is only 23%. Meanwhile, radiobromine is not used as often as radiofluorine and radioiodine isotopes; however, in some cases, radiobromine shows characteristics superior to the other radiohalogens. 76 Br is potentially useful for PET imaging because it decays with high positron abundance (55%) 15 . Although the high positron energy of 76 Br (3.4 MeV) could be a disadvantage in terms of image resolution and absorbed radiation dose 16 , the relatively longer half-life (t 1/2 = 16.1 h) of 76 Br than those of 11 C, 13 N, 15 O, and 18 F could be advantageous. Values of physical properties of the brominated derivatives, such as stability, molecular size, lipophilicity, and solubility, range between those of fluorinated and iodinated derivatives 11 . Thus, the steric effect of radiobromine might be smaller than that of radioiodine 17 68 Ga, which exhibited a high tumor-to-blood ratio and good IC 50 . The labeled affibodies clearly visualized PDGFRβ-expressing U-87 MG xenografts in mice 18, 19 . The peptide and affibodies bind to the extracellular part of PDGFRβ. Contrastingly, intracellular domains, especially adenosine triphosphate (ATP)-binding sites, could also be a promising target for PDGFRβ imaging. Radiolabeled tyrosine kinase inhibitors (TKIs), such as the 11 C-labeled imatinib 20 , 18 F-labeled dasatinib 21 , 11 C-labeled sorafenib (tumor uptake in RXF393 xenograft mice about 2.52 ± 0.33%ID/g) 22 , and 125 I-labeled sunitinib 23 , have been synthesized and evaluated in order to develop probes targeting the ATP-binding site in nuclear medicine. However, not only do they all bind PDGFRs, but also bind other RTKs, such as vascular endothelial growth factor receptors 2 (VEGFR2), BCR-ABL1, and c-KIT. Recently, we synthesized and evaluated radioiodinated 1 derivatives, In this study, we describe the development of novel radiobrominated probes for PDGFRβ imaging. The strategy of these probes are similer to that of our previous developed radioiodine-labeled probes 12 , but differece between iodine and boromine should alter their characteristics and biodistribution of the probes [25] [26] [27] , and the difference of radionuclides may give much impact in clinical nuclear medicine. Two brominated 1 derivatives,
, were designed and synthesized. Bromine was incorporated into 1 instead of iodine in 4 and 5, and their affinities for PDGFRβ were examined. Although we are interested in developing 76 Br-labeled PDGFRβ PET imaging 
Results
Synthesis of the reference compounds and their precursors. The nonradioactive brominated reference compounds, 2 and 3, were synthesized as described in Figs 2 and 3. Compound 2 was synthesized by direct bromination at C-5 position of the quinoline group of 1 using N-bromosuccinimide (NBS) (Fig. 2) . Compound 3 was obtained by acylation of the amino group of 1 using SBrB (Fig. 3) . Tributyltin precursors (6 and 7) were synthesized as described previously 24 .
Cell viability assays. The binding affinity of 2 and 3 to the ATP-binding site in PDGFRβ was evaluated using PDGFRβ overexpressed TR-PCT1 cells. Cells were treated with 1-1000 nM of synthesized ligands, 1, 2, or 3. As seen in Fig. 4, 3 showed the similar effects compared to 1. 2 was more effective in decreasing the viability of TR-PCT1 cells than 1.
Radiolabeling. Radiobrominated , and the precursors (6 and 7) were completely separated using RP-HPLC. N-chlorosuccinimide (NCS) was used as an oxidizing agent in these syntheses. The 77 Br]3 in 0.1 M phosphate-buffered saline (PBS) (pH 7.4) was high (93.6 ± 0.9% and 93.0 ± 0.6%, respectively). There was no significant decomposition after 24 h incubation at 37 °C for either radiotracer.
Cell uptake experiments. Figure 5 Biodistribution experiments. In this study, to minimize both the number of mice consumed in the experiment and the potential for experimental errors, we co-injected radiobrominated and radioiodinated compounds into mice 30, 31 . ]5 in ddY mice. High radioactivity in the liver, small intestine, and large intestine was observed. At 24 h postinjection of the radiobrominated and radioiodinated compounds, radioactivity in feces was much higher than that in urine, suggesting hepatobiliary excretion as the main excretion pathway for both radiotracers.
We investigated the biodistribution of the radiotracers in BxPC3-luc tumor-bearing mice by co-injecting 
Discussion
In our study, we performed cell viability assays of 1, 2, and 3, to evaluate the effect of the structural changes on the affinity between the ligand and the molecular target, PDGFRβ. Similar affinity was exhibited by 1 and 3, whereas 2 displayed a higher affinity than 1 (Fig. 4) . The larger size of the bromine compared with hydrogen may have contributed to this result. In accordance with 4, incorporating bromine into 1 could increase the affinity of 2 for PDGFRβ. Although the results of the cell viability assays showed the in vitro affinity of the iodinated compound 4 Figure 4 . Cell viability after exposure 1, 2, and 3 by WST-8 assay. Data were presented as mean ± SD for three samples. Significance was determined using a one-way ANOVA followed by Tukey's post hoc test ( * p < 0.01, ** p < 0.001).
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The comparison of chloramine-T, peracetic acid, and NCS in this study showed NCS was the best oxidizing agent for the bromination of 1 through an oxidative bromodestannylation reaction under non-carrier added condition (data not shown). When NCS was used, undesired radioactive peaks had almost disappeared. Previously, we reported the preparation of a 77 Br-labeled sigma-1 receptor ligand, (+)-[ 77 Br]pBrV, by using oxidative bromodestannylation with chloramine-T; its radiochemical yield was 53% 30 . Hanaoka et al. performed 77 Br labeling of α-methyl-phenylalanine by bromodestannylation reaction with NCS, and its radiochemical yield was approximately 60% 32 . In these reports, using the same corresponding precursors, the radiochemical yields for radiobromine labeling were lower than those for radioiodine labeling. (Fig. 5) . This result was consistent with the cell viability assay, in which 2 showed a higher affinity for PDGFRβ than 1 and 3. This result also agreed with the in vivo experiment in which [ 77 Br]2 showed higher accumulation in the BxPC3-luc tumor than [ 77 Br]3 ( Table 2 ). The difference in the lipophilicity may be an important factor that contributed to this result. Moreover, the excess amount of PDGFRβ ligand can reduce [ 77 Br]2 uptake in PDGFRβ-positive tumor cells (Fig. 6 ) and in the in vivo blocking experiments using tumor-bearing mice (Fig. 7) . [ Although free iodide ions generated by the deiodination of the radioiodine-labeled compounds highly accumulate in the stomach and thyroid. However, the biodistribution of free bromide ions is much different. Because the free bromide ions accumulate in blood and are retained for a long time 32, 33 , the radioactivity in the blood can be used as an in vivo stability index for radiobromine-labeled compounds. As summarized in Tables 1 and 2 Br]3 were easily prepared using a bromodestannylation reaction without carrier addition in excellent radiochemical yields and high radiochemical purities. Furthermore, 76 Br could be incorporated into 1 instead of 77 Br. Although this study suggests that radiobrominated 2 has more promising property for PET imaging of PDGFRβ than radioiodinated 4, in clinical application of the radiobrominated compound as a PDGFRβ-targeted PET imaging agent, structural modification would be required to improve tumor uptake and tumor-to-background ratios.
Methods

Materials.
Commercialy available reagents and solvents were purchased from Nacalai Tesque, Inc., (Kyoto, Japan), Wako Pure Chemical Industries (Osaka, Japan), Tokyo Chemical Industry Co., Ltd., (Tokyo, Japan), Sigma-Aldrich (St. Louis, MO, USA), and Kanto Chemical, Co., Inc. (Tokyo, Japan) and used without further purification. The radioactivity was determined by a gamma counter (AccuFLEX γ ARC-8001 Hitachi, Ltd., Tokyo, Japan). Bicinchoninic Acid (BCA) Protein Assay Kit was purchased from Nacalai Tesque. Cell Counting Kit-8 (CCK-8) was purchased from Dojindo (Kumamoto, Japan). Recombinant murine platelet-derived growth factor-BB (PDGF-BB) was purchased from PeproTech (Rocky Hill, NJ, USA). TR-PCT1 rodent brain pericyte cell line was generously obtained from Dr. Emi Nakashima (Keio University, Tokyo, Japan) 34 . BxPC3-luc cell line was obtained from JCRB Cell Bank (Ibaraki, Japan). MCF7 cell line was purchased from DS Pharma Biomedical (Osaka, Japan).
Proton and carbon nuclear magnetic resonance ( 1 H-NMR and 13 C-NMR) spectra were recorded on JEOL JNM-ECS400 (JEOL Ltd, Tokyo, Japan). Pictures of the NMR spectra are available in the Supplementary Material file. Direct analysis in real time mass spectra (DART-MS) and Electrospray ionization mass spectra (ESI-MS) were obtained with JEOL JMS-T100TD (JEOL Ltd). Purification was performed using HPLC system (LC-20AD pump, SPD-20A UV detector, and CTO-20A column oven, and DGU-20A 5R degasser, SHIMADZU, Kyoto, Japan). TLC analyses were performed with silica plates (Art 5553, Merck, Darmstadt, Germany). Optical density in WST-8 assay was determined using Infinite ® F200 Pro microplate reader (TECAN, Männedorf, Switzerland).
Synthesis of reference compounds and precursors.
Intermediate, reference compounds, 1, and corresponding tin precursors were synthesized according to the reported studies, with a slight modification 24 . 1 (144 mg, 0.4 mmol, 1 .0 eq.) was dissolved in acetic acid (5 mL). To the solution, NBS (72 mg, 0.4 mmol, 1.0 eq.) was added in one portion and the mixture was stirred overnight at room temperature. pH was adjusted to 9.0 with saturated aqueous NaHCO 3 and the mixture was extracted using 
1-{5-Bromo-2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl} piperidin-4-amine (2).
N-3-bromobenzoyl-1-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]-quinolin-8-yl}-piperidin-4-amine (3).
A mixture of 1 (15 mg, 37.5 µmol, 1.0 eq.), N,N-diisopropylethylamine (DIPEA) (10 µL, 56.2 µmol, 1.5 eq.), and N-succinimidyl-3-bromobenzoate (SBrB) (12 mg, 41.2 µmol, 1.1 eq.) in anhydrous DCM (1 mL) was stirred at 50 °C for 2 h under N 2 atmosphere. Then the mixture was diluted with DCM (15 mL), washed with water (3 × 15 mL), dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by SiO 2 column chromatography (eluent: chloroform/methanol = 100/1) to yield 3 (18 mg, 80%) as a colorless solid. 19 (1H, s) . 13 Cell viability assays. The cell viability assay of brominated compounds, 2 and 3, was evaluated as described previously 24, 27 . Namely, TR-PCT1 cells were seeded on 96-well plates (5 × 10 3 cells/well) and cultured at 33 °C in DMEM medium with 20 ng/mL PDGF-BB and 2% FBS in a 5% CO 2 incubator. Cells were treated with each compound for 72 h and cell viability was determined by the Cell Counting Kit-8.
Production of bromine-77. 77 Br was produced at University of Fukui. Radiosynthesis isolation and purification of 77 Br were performed according to a previously reported method from a 77 Se(p,n) 77 Br reaction on an isotopically enriched Cu 2 77 Se coated tungsten target with 8 µA/11 MeV proton beam on a RDS Eclipse HP/RD cyclotron (Siemens, Knoxville, TN, USA) 30 .
Radiolabeling. Radiotracers, [
77 Br]2 and [
77 Br]3, were prepared by a bromodestannylation reaction using the corresponding tin precursors (6 or 7) and NCS as an oxidizing agent. The radiolabeled compounds were purified by reversed phase (RP)-HPLC performed with a Cosmosil 5C 18 -MS-II column (4.6 × 150 mm; Nacalai Tesque) at the flow rate of 1 mL/min with a gradient mobile phase of 70% methanol in water with 0.05% TEA to 90% methanol in water with 0.05% TEA for 20 min. The column temperature was 40 °C. Radiochemical yield and radiochemical purity were calculated by counting radioactivity using an auto well gamma counter. The mixture was heated to 60 °C for 30 min and shaken every 10 min during heating, then quenched by addition of sodium hydrogensulfite (5 mg/mL, 10 µL), and the solvent was removed by N 2 gassing. Trifluoroacetic acid (TFA) was added to the residue and the shaking was allowed to continue for 30 min. After removing TFA by N 2 gassing, the residue was mixed with the initial mobile phase of HPLC. The reaction mixture was shaken for some minutes, filtered, and purified by HPLC. 77 Br]3 into n-octanol and 0.1 M phosphate buffer (PB) pH 7.4 were determined using the method described previously 24 . The measurement was performed in quadruplicate. The partition coefficient was determined by calculating the ratio of cpm/mL of n-octanol to that of buffer and expressed as log P. Radioactivity of each layer were counted by a gamma counter.
Synthesis of [
In vitro stability experiments. The stability of radiolabeled compounds, [ 77 
Br]2 and [
77 Br]3, were analyzed as described previously 24 . The purities radiolabeled compounds were determined by TLC using chloroform/ I]4 at 1 h postinjection with 1 (40 mg/kg) (blocking group) or no treatment control group. Data were presented as means ± SD for three or four mice. Significance was determined using an unpaired Student's t-test ( * p < 0.05, ** p < 0.01).
